Summary of findings table ‐ Recombinant activated factor VII vs placebo
Serious adverse events by total adverse events · patients with upper gastrointestinal bleeding and liver diseases.
Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).
1 finding from 1 review
- Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases 2012 · Cochrane Headline outcomes onlyRR 0.9 [0.73, 1.09]2 studies · 1043 participantsHigh